Figure 1: NYHA Functional Class at presentation in pulmonary arterial hypertension (PAH)
Despite greater awareness of PAH in recent years and the availability of targeted therapies, the majority of patients are at an advanced symptomatic stage by the time they are diagnosed.3 A French registry of 674 patients has highlighted that 75% of patients were in New York Heart Association (NYHA) Class III or IV at presentation (figure 1).3
Clinical investigations to date have focused largely on these more compromised patient populations. However, some recent studies have included patients in the early symptomatic stages of the disease. This is suppor